Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Dik Kwekkeboom, W.W. de Herder, Eric Krenning

Research output: Contribution to journalArticleAcademicpeer-review

57 Citations (Scopus)

Abstract

Treatment with radiolabeled somatostatin analogs is a promising tool in the management of patients with inoperable or metastasized neuroendocrine tumors. Symptomatic improvement may occur with all (111)Indium-, (90)Yttrium-, or (177)Lutetium-labeled somatostatin analogs used for peptide receptor radionuclide therapy. If kidney protective agents are used, the side-effects are few and mild, and the median duration of the therapy response is 30 and 40 months, respectively. Overall survival is several years from diagnosis. These data compare favorably with the limited number of alternative treatments. If more widespread use of PRRT can be guaranteed, such therapy may become the therapy of first choice.
Original languageUndefined/Unknown
Pages (from-to)173-+
JournalEndocrinology & Metabolism Clinics of North America
Volume40
Issue number1
DOIs
Publication statusPublished - 2011

Research programs

  • EMC MM-01-39-01
  • EMC MM-01-40-01

Cite this